Communications Biology (Mar 2022)
Characterisation of PDGF-BB:PDGFRβ signalling pathways in human brain pericytes: evidence of disruption in Alzheimer’s disease
- Leon C. D. Smyth,
- Blake Highet,
- Deidre Jansson,
- Jane Wu,
- Justin Rustenhoven,
- Miranda Aalderink,
- Adelie Tan,
- Susan Li,
- Rebecca Johnson,
- Natacha Coppieters,
- Renee Handley,
- Pritika Narayan,
- Malvindar K. Singh-Bains,
- Patrick Schweder,
- Clinton Turner,
- Edward W. Mee,
- Peter Heppner,
- Jason Correia,
- Thomas I.-H. Park,
- Maurice A. Curtis,
- Richard L. M. Faull,
- Mike Dragunow
Affiliations
- Leon C. D. Smyth
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Blake Highet
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Deidre Jansson
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Jane Wu
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Justin Rustenhoven
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Miranda Aalderink
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Adelie Tan
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Susan Li
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Rebecca Johnson
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Natacha Coppieters
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Renee Handley
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Pritika Narayan
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Malvindar K. Singh-Bains
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Patrick Schweder
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Clinton Turner
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Edward W. Mee
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Peter Heppner
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Jason Correia
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Thomas I.-H. Park
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- Maurice A. Curtis
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Richard L. M. Faull
- Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland
- Mike Dragunow
- Department of Pharmacology and Clinical Pharmacology, Faculty of Medical and Health Sciences, University of Auckland
- DOI
- https://doi.org/10.1038/s42003-022-03180-8
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 16
Abstract
Smyth et al. use tissue microarrays from Alzheimer’s disease (AD) patient brains to show that PDGF-BB:PDGFRβ signalling components are reduced in AD. They then use primary human brain pericytes to elucidate a pathway by which PDGF-BB:PDGFRβ signalling in brain pericytes is disrupted in AD, thus impairing the blood brain barrier.
